
Anita H Clayton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9274894/publications.pdf Version: 2024-02-01



ΔΝΙΤΑ Η ΟΙΑΥΤΟΝ

#	Article	IF	CITATIONS
1	Validation of the Female Sexual Distress Scale-Revised for Assessing Distress in Women with Hypoactive Sexual Desire Disorder. Journal of Sexual Medicine, 2008, 5, 357-364.	0.6	470
2	Prevalence of Sexual Dysfunction Among Newer Antidepressants. Journal of Clinical Psychiatry, 2002, 63, 357-366.	2.2	450
3	Positron-Emission Tomography and Personality Disorders. Neuropsychopharmacology, 1994, 10, 21-28.	5.4	244
4	Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstetrics and Gynecology, 2019, 134, 899-908.	2.4	242
5	15 Years of Clinical Experience With Bupropion HCl. Primary Care Companion To the Journal of Clinical Psychiatry, 2005, 7, 106-13.	0.6	225
6	Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics and Gynecology, 2019, 134, 909-917.	2.4	186
7	Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?. Expert Opinion on Pharmacotherapy, 2007, 8, 457-466.	1.8	180
8	A Placebo-Controlled Trial of Bupropion SR as an Antidote for Selective Serotonin Reuptake Inhibitor–Induced Sexual Dysfunction. Journal of Clinical Psychiatry, 2004, 65, 62-67.	2.2	178
9	Reliability and Construct Validity of the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14). Journal of Sex and Marital Therapy, 2006, 32, 43-52.	1.5	176
10	The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. Mayo Clinic Proceedings, 2018, 93, 467-487.	3.0	166
11	Bupropion Sustained Release for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women. Journal of Clinical Psychopharmacology, 2004, 24, 339-342.	1.4	163
12	Hypoactive Sexual Desire Disorder. Mayo Clinic Proceedings, 2017, 92, 114-128.	3.0	158
13	Clinical Evaluation and Management Strategy for Sexual Dysfunction in Men and Women. Journal of Sexual Medicine, 2004, 1, 49-57.	0.6	155
14	Validation of the Decreased Sexual Desire Screener (DSDS): A Brief Diagnostic Instrument for Generalized Acquired Female Hypoactive Sexual Desire Disorder (HSDD). Journal of Sexual Medicine, 2009, 6, 730-738.	0.6	135
15	Reliability and Validity of the Sexual Interest and Desire Inventory–Female (SIDI-F), a Scale Designed to Measure Severity of Female Hypoactive Sexual Desire Disorder. Journal of Sex and Marital Therapy, 2006, 32, 115-135.	1.5	133
16	Antidepressants and Sexual Dysfunction: Mechanisms and Clinical Implications. Postgraduate Medicine, 2014, 126, 91-99.	2.0	117
17	Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions—Part II. Journal of Sexual Medicine, 2016, 13, 1888-1906.	0.6	116
18	Changes in Sexual Functioning Associated with Duloxetine, Escitalopram, and Placebo in the Treatment of Patients with Major Depressive Disorder. Journal of Sexual Medicine, 2007, 4, 917-929.	0.6	115

#	Article	IF	CITATIONS
19	Bupropion Extended Release Compared With Escitalopram. Journal of Clinical Psychiatry, 2006, 67, 736-746.	2.2	114
20	The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder. CNS Drugs, 2015, 29, 915-933.	5.9	103
21	Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opinion on Drug Safety, 2014, 13, 1361-1374.	2.4	100
22	Burden of phase-specific sexual dysfunction with SSRIsâ [~] †. Journal of Affective Disorders, 2006, 91, 27-32.	4.1	99
23	Serotonin 2A â~'1438 G/A and G-Protein Beta3 Subunit C825T Polymorphisms in Patients with Depression and SSRI-Associated Sexual Side-Effects. Neuropsychopharmacology, 2006, 31, 2281-2288.	5.4	90
24	Distressing Sexual Problems in United States Women Revisited. Journal of Clinical Psychiatry, 2009, 70, 1698-1706.	2.2	85
25	ORIGINAL ARTICLES: Epidemiology and Neurobiology of Female Sexual Dysfunction. Journal of Sexual Medicine, 2007, 4, 260-268.	0.6	84
26	A Double-blind Comparison Between Bupropion XL and Venlafaxine XR. Journal of Clinical Psychopharmacology, 2006, 26, 482-488.	1.4	80
27	Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. Journal of Sexual Medicine, 2015, 12, 2036-2048.	0.6	78
28	Female Sexual Dysfunction. Medical Clinics of North America, 2019, 103, 681-698.	2.5	76
29	Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Women's Health, 2016, 12, 325-337.	1.5	75
30	Substitution of an SSRI With Bupropion Sustained Release Following SSRI-Induced Sexual Dysfunction. Journal of Clinical Psychiatry, 2001, 62, 185-190.	2.2	70
31	The blood brain barrier and the role of cytokines in neuropsychiatry. Psychiatry, 2009, 6, 18-22.	0.3	68
32	The pathophysiology of hypoactive sexual desire disorder in women. International Journal of Gynecology and Obstetrics, 2010, 110, 7-11.	2.3	66
33	Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. International Clinical Psychopharmacology, 2003, 18, 151-156.	1.7	65
34	The Impact of Physical Illness on Sexual Dysfunction. , 2008, 29, 70-88.		62
35	Psychological Treatment Trials for Hypoactive Sexual Desire Disorder: A Sexual Medicine Critique and Perspective. Journal of Sexual Medicine, 2015, 12, 2451-2458.	0.6	57
36	Sexual Dysfunction Due to Psychotropic Medications. Psychiatric Clinics of North America, 2016, 39, 427-463.	1.3	56

#	Article	IF	CITATIONS
37	An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder. CNS Spectrums, 2009, 14, 183-195.	1.2	55
38	Symptoms Related to the Menstrual Cycle: Diagnosis, Prevalence, and Treatment. Journal of Psychiatric Practice, 2008, 14, 13-21.	0.7	54
39	Female Sexual Dysfunction. Psychiatric Clinics of North America, 2017, 40, 267-284.	1.3	53
40	ORIGINAL RESEARCH—WOMEN's SEXUAL DYSFUNCTIONS: The Sexual Interest and Desire Inventory—Female (SIDIâ€F): Item Response Analyses of Data from Women Diagnosed with Hypoactive Sexual Desire Disorder. Journal of Sexual Medicine, 2005, 2, 801-818.	0.6	50
41	GAD65 antibodies, chronic psychosis, and type 2 diabetes mellitus. Innovations in Clinical Neuroscience, 2011, 8, 34-6.	0.1	50
42	Sexual function and dysfunction in women. Psychiatric Clinics of North America, 2003, 26, 673-682.	1.3	49
43	Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder. Journal of Clinical Psychiatry, 2013, 74, 1010-1017.	2.2	49
44	Female Sexual Interest/Arousal Disorder: A Diagnosis Out of Thin Air. Archives of Sexual Behavior, 2014, 43, 1227-1229.	1.9	48
45	Continuing Medical Education: The Impact of Mental Illness and Psychotropic Medications on Sexual Functioning: The Evidence and Management (CME). Journal of Sexual Medicine, 2009, 6, 1200-1211.	0.6	47
46	The Effect of Vilazodone on Sexual Function During the Treatment of Major Depressive Disorder. Journal of Sexual Medicine, 2013, 10, 2465-2476.	0.6	47
47	Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause, 2010, 17, 700-711.	2.0	46
48	Should Sexual Desire and Arousal Disorders in Women Be Merged?. Archives of Sexual Behavior, 2011, 40, 217-219.	1.9	46
49	Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectrums, 2016, 21, 367-378.	1.2	45
50	The Evolution of the Female Sexual Disorder/Dysfunction Definitions, Nomenclature, and Classifications: A Review of DSM, ICSM, ISSWSH, and ICD. Sexual Medicine Reviews, 2021, 9, 36-56.	2.9	43
51	Evaluation and Management of Hypoactive Sexual Desire Disorder. Sexual Medicine, 2018, 6, 59-74.	1.6	42
52	Female sexual dysfunction related to depression and antidepressant medications. Current Women's Health Reports, 2002, 2, 182-7.	0.2	42
53	Intended or Unintended Consequences? The Likely Implications of Raising the Bar for Sexual Dysfunction Diagnosis in the Proposed DSM-V Revisions: 1. For Women with Incomplete Loss of Desire or Sexual Receptivity. Journal of Sexual Medicine, 2012, 9, 2027-2039.	0.6	38
54	Standards for Clinical Trials in Sexual Dysfunction in Women: Research Designs and Outcomes Assessment. Journal of Sexual Medicine, 2010, 7, 541-560.	0.6	37

#	Article	IF	CITATIONS
55	Validation of the Sexual Interest and Desire Inventory-Female in Hypoactive Sexual Desire Disorder. Journal of Sexual Medicine, 2010, 7, 3918-3928.	0.6	37
56	Chronic episodic disorders in women. Psychiatric Clinics of North America, 2003, 26, 725-740.	1.3	35
57	Female Sexual Dysfunction. Psychiatric Clinics of North America, 2010, 33, 323-338.	1.3	35
58	Menopausal Status in Breast Cancer Patients with Past Chemotherapy Determines Long-Term Hypoactive Sexual Desire Disorder. Journal of Sexual Medicine, 2011, 8, 1486-1494.	0.6	35
59	Physician Attitudes Regarding Hypoactive Sexual Desire Disorder in a Primary Care Clinic: A Pilot Study. Journal of Sexual Medicine, 2008, 5, 640-645.	0.6	34
60	Assessment of sexual functioning during the menstrual cycle. Journal of Sex and Marital Therapy, 1999, 25, 281-291.	1.5	33
61	Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder. Journal of Clinical Psychiatry, 2015, 76, 562-569.	2.2	32
62	Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial. Journal of Sexual Medicine, 2019, 16, 1638-1649.	0.6	29
63	Major depressive disorder, antidepressants, and sexual dysfunction. Journal of Clinical Psychiatry, 2006, 67 Suppl 6, 33-7.	2.2	29
64	Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo. International Clinical Psychopharmacology, 2015, 30, 216-223.	1.7	28
65	Intended or Unintended Consequences? The Likely Implications of Raising the Bar for Sexual Dysfunction Diagnosis in the Proposed DSMâ€V Revisions: 2. For Women with Loss of Subjective Sexual Arousal. Journal of Sexual Medicine, 2012, 9, 2040-2046.	0.6	27
66	Depression in Premenopausal Women With HSDD. Psychosomatic Medicine, 2012, 74, 305-311.	2.0	26
67	Flibanserin: From Bench to Bedside. Sexual Medicine Reviews, 2017, 5, 461-469.	2.9	26
68	Validity of the Decreased Sexual Desire Screener for Diagnosing Hypoactive Sexual Desire Disorder. Journal of Sex and Marital Therapy, 2013, 39, 132-143.	1.5	24
69	Symptoms of Sexual Dysfunction in Patients Treated for Major Depressive Disorder. Journal of Clinical Psychiatry, 2007, 68, 1860-1866.	2.2	24
70	Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender–age interactions. International Clinical Psychopharmacology, 2007, 22, 226-229.	1.7	23
71	Cutoff Score of the Sexual Interest and Desire Inventory-Female for Diagnosis of Hypoactive Sexual Desire Disorder. Journal of Women's Health, 2010, 19, 2191-2195.	3.3	23
72	An Evaluation of Sexual Functioning in Employed Outpatients with Major Depressive Disorder Treated with Desvenlafaxine 50mg or Placebo. Journal of Sexual Medicine, 2013, 10, 768-776.	0.6	23

#	Article	IF	CITATIONS
73	Female Sexual Dysfunction. Obstetrics and Gynecology Clinics of North America, 2009, 36, 861-876.	1.9	22
74	eDiary and Female Sexual Distress Scale [©] in Evaluating Distress in Hypoactive Sexual Desire Disorder (HSDD). Journal of Sex Research, 2011, 48, 565-572.	2.5	22
75	Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. CNS Spectrums, 2020, 25, 50-63.	1.2	22
76	Analysis by Age and Sex of Efficacy Data From Placebo-Controlled Trials of Desvenlafaxine in Outpatients With Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2010, 30, 294-299.	1.4	21
77	A Pooled Analysis of the Efficacy of Desvenlafaxine for the Treatment of Major Depressive Disorder in Perimenopausal and Postmenopausal Women. Journal of Women's Health, 2015, 24, 281-290.	3.3	20
78	Assessing the Onset of Antidepressant-Induced Sexual Dysfunction Using Interactive Voice Response Technology. Journal of Clinical Psychiatry, 2007, 68, 525-532.	2.2	20
79	Etiology of Female Sexual Dysfunction. Women's Health, 2013, 9, 135-137.	1.5	18
80	Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. BMC Research Notes, 2014, 7, 459.	1.4	18
81	Clinical role of brexpiprazole in depression and schizophrenia. Therapeutics and Clinical Risk Management, 2017, Volume 13, 299-306.	2.0	18
82	Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. Menopause, 2014, 21, 799-806.	2.0	17
83	Effects of vilazodone on sexual functioning in healthy adults. International Clinical Psychopharmacology, 2017, 32, 27-35.	1.7	17
84	Assessment of Sexual Desire for Clinical Trials of Women With Hypoactive Sexual Desire Disorder: Measures, Desire-Related Behavior, and Assessment of Clinical Significance. Sexual Medicine Reviews, 2018, 6, 367-383.	2.9	16
85	Female Sexual Dysfunctions: What Controversy?. Journal of Clinical Psychiatry, 2006, 67, 991-992.	2.2	16
86	Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies. Neuropsychiatric Disease and Treatment, 2016, 12, 1467.	2.2	15
87	Sexual Function Across Aging. Current Psychiatry Reports, 2016, 18, 28.	4.5	15
88	Evaluation of safety for flibanserin. Expert Opinion on Drug Safety, 2020, 19, 1-8.	2.4	15
89	The Effect of Gepirone-ER in the Treatment of Sexual Dysfunction in Depressed Men. Journal of Sexual Medicine, 2012, 9, 821-829.	0.6	14
90	Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. Clinical Therapeutics, 2017, 39, 514-526.e14.	2.5	14

#	Article	IF	CITATIONS
91	Expert opinion on existing and developing drugs to treat female sexual dysfunction. Expert Opinion on Emerging Drugs, 2018, 23, 223-230.	2.4	14
92	Recognition of depression among women presenting with menopausal symptoms. Menopause, 2008, 15, 758-767.	2.0	13
93	Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. Journal of Sexual Medicine, 2019, 16, 1226-1235.	0.6	12
94	Safety of Flibanserin in Women Treated With Antidepressants: A Randomized, Placebo-Controlled Study. Journal of Sexual Medicine, 2018, 15, 43-51.	0.6	11
95	Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. International Clinical Psychopharmacology, 2003, 18, 151-156.	1.7	10
96	Glutamic acid decarboxylase (GAD) antibodies in tardive dyskinesia (TD) as compared to patients with schizophrenia without TD and normal controls. Schizophrenia Research, 2008, 105, 287-288.	2.0	10
97	Effect of Lurasidone on Sexual Function in Major Depressive Disorder Patients With Subthreshold Hypomanic Symptoms (Mixed Features). Journal of Clinical Psychiatry, 2018, 79, .	2.2	10
98	Sexual Functioning of Latino Women Seeking Outpatient Gynecologic Care. Journal of Sexual Medicine, 2009, 6, 61-69.	0.6	9
99	Sex Differences in the Treatment of Sexual Dysfunction. Current Psychiatry Reports, 2018, 20, 18.	4.5	9
100	Effect Size in Efficacy Trials of Women With Decreased Sexual Desire. Sexual Medicine Reviews, 2018, 6, 358-366.	2.9	9
101	The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectrums, 2022, 27, 281-289.	1.2	9
102	Addressing sexual concerns of female breast cancer survivors and partners: a qualitative study of survivors, partners, and oncology providers about Internet intervention preferences. Supportive Care in Cancer, 2021, 29, 7451-7460.	2.2	9
103	What Sexual Behaviors Relate to Decreased Sexual Desire in Women? A Review and Proposal for End Points in Treatment Trials for Hypoactive Sexual Desire Disorder. Sexual Medicine, 2017, 5, e73-e83.	1.6	8
104	Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women. Journal of Sexual Medicine, 2019, 16, 1885-1894.	0.6	8
105	Effect of Brexpiprazole on Prolactin and Sexual Functioning. Journal of Clinical Psychopharmacology, 2020, 40, 560-567.	1.4	8
106	Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin. Sexual Medicine, 2022, 10, 100476-100476.	1.6	8
107	Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management. Expert Opinion on Drug Safety, 2022, 21, 913-930.	2.4	8
108	Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder. International Clinical Psychopharmacology, 2015, 30, 307-315.	1.7	7

#	Article	IF	CITATIONS
109	Effects of Alcohol Administered with Flibanserin in Healthy Premenopausal Women: A Randomized, Double-Blind, Single-Dose Crossover Study. Journal of Sexual Medicine, 2020, 17, 83-93.	0.6	7
110	Prevalence of Substance Misuse in New Patients in an Outpatient Psychiatry Clinic Using a Prescription Monitoring Program. primary care companion for CNS disorders, The, 2014, 16, .	0.6	7
111	Safety and Tolerability of Evening Ethanol Consumption and Bedtime Administration of Flibanserin in Healthy Premenopausal Female Subjects. Sexual Medicine, 2019, 7, 418-424.	1.6	6
112	Effects of Timing of Flibanserin Administration Relative to Alcohol Intake in Healthy Premenopausal Women: A Randomized, Double-Blind, Crossover Study. Journal of Sexual Medicine, 2019, 16, 1779-1786.	0.6	6
113	Evaluation of Flibanserin Safety: Comparison with Other Serotonergic Medications. Sexual Medicine Reviews, 2019, 7, 380-392.	2.9	5
114	Including partners in discussions of sexual side effects from breast cancer: a qualitative study of survivors, partners, and providers. Supportive Care in Cancer, 2022, 30, 4935-4944.	2.2	5
115	The Design and Evaluation of a Group Research Experience During Psychiatric Residency Training. Academic Psychiatry, 2001, 25, 68-76.	0.9	4
116	Combination Therapy in the Treatment of Major Depressive Disorder Complicated by Fibromyalgia and Menopause. Psychosomatics, 2002, 43, 491-493.	2.5	4
117	Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate. CNS Spectrums, 2014, 19, 182-196.	1.2	4
118	Is Flibanserin Meaningfully Superior to Placebo?. Journal of Sex and Marital Therapy, 2017, 43, 218-222.	1.5	4
119	Efficacy of Bremelanotide for HSDD in Women: RECONNECT Open-Label Extension Phase Results [8Q]. Obstetrics and Gynecology, 2018, 131, 186S-186S.	2.4	4
120	Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of Women's Health, 2022, 31, 391-400.	3.3	4
121	Hypoactive Sexual Desire Disorder: Separating Fact from Fiction. CNS Spectrums, 2016, 21, 9-11.	1.2	3
122	Quantitative and Qualitative Research in HSDD: The Difference Between Testing Theory and Generating New Theories. Journal of Sex and Marital Therapy, 2017, 43, 223-227.	1.5	3
123	Instruments for Screening, Diagnosis, and Management of Patients with Generalized Acquired Hypoactive Sexual Desire Disorder. Journal of Women's Health, 2020, 29, 806-814.	3.3	3
124	Treatment of Hypoactive Sexual Desire Disorder Among Women: General Considerations and Pharmacological Options. Focus (American Psychiatric Publishing), 2021, 19, 39-45.	0.8	3
125	The Impact of Antidepressant-Associated Sexual Dysfunction on Treatment Adherence in Patients with Major Depressive Disorder. Current Psychiatry Reviews, 2013, 9, 293-301.	0.9	3
126	Understanding Antidepressant Mechanism of Action and Its Effect on Efficacy and Safety. Journal of Clinical Psychiatry, 2012, 73, e11.	2.2	3

#	Article	IF	CITATIONS
127	The blood brain barrier and the role of ratiometric molecular analysis in schizophrenia. Psychiatry, 2010, 7, 20-3.	0.3	3
128	Response to Balon's Commentary: Is Basson's Model of Sexual Response Relevant?. Journal of Sex and Marital Therapy, 2021, , 1-3.	1.5	3
129	Models vs. Realities in Female Sexual Dysfunction. Journal of Sexual Medicine, 2015, 12, 1977-1978.	0.6	2
130	Standards in Studies of Psychotherapy and Pharmacotherapy Interventions for HSDD. Journal of Sex and Marital Therapy, 2017, 43, 206-209.	1.5	2
131	Lumping, Splitting, and Treating: Therapies Are Needed for Women With Overlapping Sexual Dysfunctions. Sexual Medicine Reviews, 2019, 7, 551-558.	2.9	2
132	Potential Role of Androgens in the Treatment of Hypoactive Sexual Desire in Women. Women's Health, 2005, 1, 191-193.	1.5	1
133	A Brief Version of the Sexual Interest and Desire Inventory–Female With 4 Core Items. Journal of Sexual Medicine, 2018, 15, 1370-1371.	0.6	1
134	Single Nucleotide Polymorphisms and the Central Nervous System: Potential Biomarkers in Identifying Suicide Risk. Innovations in Clinical Neuroscience, 2017, 14, 21-24.	0.1	1
135	Women's Mental Health: Progress and Realities. Psychiatric Clinics of North America, 2017, 40, xiii-xiv.	1.3	0
136	An Innovative Model of Behavior Management to Address Behavioral Emergencies in the Acute Medical Inpatient Setting: Pilot Data. Journal of Clinical Psychology in Medical Settings, 2022, 29, 54-61.	1.4	0
137	Insomnia and attention deficit hyperactivity disorder in pediatrics: a checklist for parents. Innovations in Clinical Neuroscience, 2013, 10, 19-22.	0.1	0
138	Pharmacotherapy for Sexual Dysfunction in Women. Current Psychiatry Reports, 2022, , 1.	4.5	0
139	Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of Women's Health, 2022, 31, 171-182.	3.3	0